An internal standard for the quantification of formoterol
Related Products
Unlabeled Version(s)
15584Formoterol (hemifumarate hydrate)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Formoterol-13C-d3 (hemifumarate)

Item No. 25317

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
rel-N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-(methoxy-13C-d3)phenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide, 2E-butenedioate (2:1)
Molecular Formula
C18[13C]H21D3N2O4 • 1/2C4H4O4
Formula Weight
406.5
Purity
≥99% deuterated forms (d1-d3)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: 20 mg/mlMethanol: 1 mg/mlWater: Slightly Soluble
SMILES
OC(C=C1)=C(NC([H])=O)C=C1[C@H](O)CN[C@@H](C)CC2=CC=C(O[13C]([2H])([2H])[2H])C=C2.OC(/C=C/C(O)=O)=O
InChi Code
InChI=1S/2C19H24N2O4.C4H4O4/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*13-,19+;/m00./s1/i2*2+1D3;
InChi Key
OBRNDARFFFHCGE-RPXDEYMZSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $202

    Add

    1 mg

    $361

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Formoterol-13C-d3 is intended for use as an internal standard for the quantification of formoterol (Item No. 15584) by GC- or LC-MS. Formoterol is a selective agonist of the β2-adrenergic receptor (β2-AR; Kis = 7.58 and 2,630 nM for β2- and β1-ARs, respectively).1 It is selective for β-ARs in isolated guinea pig trachea over those in atrial tissue (pD2s = 9.29 and 6.98, respectively) and has a long duration of action.2,1 Aerosolized formoterol (10 µg/ml, inhaled) prevents the late asthmatic response and eosinophil and macrophage infiltration in bronchoalveolar lavage fluid (BALF), and as well as reduces bronchial reactivity in a guinea pig model of allergic asthma induced by ovalbumin.3 Formulations containing formoterol have been used, alone and in combination with other compounds, in the treatment of chronic obstructive pulmonary disease and asthma.4,5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Anderson, G.P. Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator. Life Sci. 52(26), 2145-2160 (1993).

    2. Decker, N., Quennedey, M.C., Rouot, B., et al. Effects of N-aralkyl substitution of β-agonists on α- and β-adrenoceptor subtypes: Pharmacological studies and binding assays. J. Pharm. Pharmacol. 34(2), 107-112 (1982).

    3. Sugiyama, H., Okada, C., Bewtra, A.K., et al. The effect of formoterol on the late asthmatic phenomena in guinea pigs. J. Allergy Clin. Immunol. 89(4), 858-866 (1992).

    4. Decramer, M.L., Hanania, N.A., Lötvall, J.O., et al. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 8, 53-64 (2013).

    5. Tashkin, D.P., and Ferguson, G.T. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir. Res. 14(1), 49 (2013).

    6. Bush, A., and Saglani, S. Management of severe asthma in children. Lancet 376(9743), 814-825 (2010).